4 Years Of Direct-Acting Antivirals (Daas) In The German Hepatitis C-Registry (Dhc-R)

Background More than 250000 patients suffer from chronic hepatitis C in Germany. Several potent, direct-acting antiviral drugs have been approved since 2014. The aim of the German Hepatitis C-Registry (DHC-R) is to describe the epidemiology and patient care of hepatitis C and to investigate the efficacy and safety of new treatment options in real-world settings. Methods The DHC-R is a prospective multicenter non-interventional registry study that includes 327 centers throughout Germany. All approved treatment options have been documented. The current analysis differentiated 4 phases: 2/2014-12/2014, 1/2015-12/2015, 1/2016-7/2017 and 8/2017-7/2018. Findings Between February 2014 and July 2018, 12170 patients were included in the registry (61.3% male), and antiviral treatment was initiated in 11268. The mean age declined from 52.3 years (phase 1) to 49.3 years (phase 4), while the proportion of patients with previous or ongoing drug abuse increased (26.3% to 43.1%). In 2014, 35.1% of treated patients had liver cirrhosis, which declined to 16.5% in phase 4. The HCV genotype distribution showed marked fluctuations, with most recent increases in HCV genotype 3 (30% in phase 4). Per-protocol sustained virological response rates increased from 92.8% in 2014 to 94.4% in 2017/18 with excellent tolerability. Summary The DHC-R mirrors patient care of chronic hepatitis in the real-world setting in Germany and provides insights into epidemiology developments. It also confirms the high efficacy and safety of novel treatment options.